Certara (NASDAQ:CERT) Stock Price Down 4.4%

Certara, Inc. (NASDAQ:CERT) traded down 4.4% during mid-day trading on Wednesday . The company traded as low as $11.85 and last traded at $11.90. 37,809 shares traded hands during trading, a decline of 94% from the average session volume of 587,755 shares. The stock had previously closed at $12.45.

Analyst Ratings Changes

Several analysts have commented on the company. KeyCorp reduced their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. UBS Group decreased their price target on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Barclays lowered their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, Robert W. Baird dropped their price target on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $18.56.

Certara Price Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. The stock’s fifty day moving average price is $14.73 and its 200-day moving average price is $16.42. The firm has a market cap of $1.90 billion, a PE ratio of -31.92, a P/E/G ratio of 5.39 and a beta of 1.52.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. During the same period last year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank grew its holdings in Certara by 1.7% in the fourth quarter. Comerica Bank now owns 55,469 shares of the company’s stock valued at $976,000 after purchasing an additional 929 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Certara by 1.6% in the 1st quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company’s stock worth $1,375,000 after buying an additional 1,191 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in Certara by 2.3% in the 2nd quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock valued at $751,000 after acquiring an additional 1,200 shares during the last quarter. Texas Permanent School Fund Corp grew its stake in Certara by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 93,729 shares of the company’s stock valued at $1,676,000 after acquiring an additional 1,213 shares during the last quarter. Finally, Pineridge Advisors LLC purchased a new position in Certara during the 4th quarter valued at about $28,000. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.